Novel Androgen Receptor Degrader for Androgenetic Alopecia (AGA) Application
April 2023
in “
Journal of Investigative Dermatology
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → Studysummary In this study, a novel AR protein degrader was shown to reverse DHT-induced hair regrowth delay in a mouse model of androgenetic alopecia, with minimal circulation and potential side effects.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This study addresses androgenetic alopecia (AGA), a prevalent hair loss disorder, by developing novel androgen receptor (AR) degraders. These degraders specifically target and degrade AR protein, which is implicated in AGA due to increased dihydrotestosterone (DHT) and AR levels. The AR-degrader demonstrated efficacy in LNCaP cells with a low nanomolar DC50 and reversed DHT-induced hair regrowth inhibition in a mouse model. Topical application resulted in minimal systemic absorption, suggesting a lower risk of side effects compared to oral treatments like finasteride. This novel AR-degrader offers a promising, efficient, and safe therapeutic option for AGA.
